

RNS Number : 8654N
Sareum Holdings PLC
27 November 2024

Sareum Holdings PLC

("Sareum" or the "Company")

Notice of AGM, Annual Report and Accounts

Cambridge, UK, 27 November 2024- Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces that the Company's Annual General Meeting ("AGM") will be held at 10.00am on Thursday 19 December 2024 at 88 Wood Street, London, EC2V 7QR.

Shareholders wishing to attend in person are requested to register their details at info@sareum.co.uk in advance, or else bring a copy of the notice of AGM (available on the Company's website www.sareum.com/results-reports) and present it at 88 Wood Street reception.

In order to allow shareholders to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company ("IMC") platform. Shareholders who wish to follow the AGM online should register for the event in advance by using the following link: www.investormeetcompany.com/sareum-holdings-plc/register-investor.

Shareholders are invited to submit questions for the Board to consider in the Q&A session to be held immediately after the AGM. Questions can be pre submitted via the IMC Platform up until 9.00am the day before the meeting and can be submitted at any time during the AGM itself. Shareholders are reminded that following the AGM online will not constitute attendance at the AGM and therefore will not be able to vote on the day.

Shareholders intending to vote should do so via the shareholder portal at www.signalshares.com where details of the procedure are shown. Alternatively, shareholders may request a paper form of proxy from our registrars, Link Group.

The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2024, will be posted shortly to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website: www.sareum.com/results-reports

For further information, please contact:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700
ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Corporate Broker)

Claire Noyce

020 3764 2341

ICR Healthcare (Financial PR)

Jessica Hodgson / Davide Salvi / Kumail Waljee

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAUBOKRSOUAURA